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Introduction  
TNF-related apoptosis-inducing ligand (TRAIL) is 
a important protein expressed by Natural Killer 
cells within the immune system.  
It induces apoptosis preferentially in cancer cells 
and is a potential therapeutic target 
Many tumours are TRAIL-resistant,  and TRAIL-
resistance emerges readily during therapy. 
TRAIL-sensitisors may overcome both existing, 
and emerging TRAIL insensitivity (see Fig 1) 
Non-proliferative quiescence cancer stem cell-
like cells are TRAIL-resistant in some tumour 
models (Cross, NA. Unpublished observations).  
Translational reprogramming agents such is EIF2 
inhibitors may overcome the quiescent 
phenotype and sensitise cells to (Schewe & 
Aguirre-Ghiso, 2009). 
 
 
 
Investigation of Translational reprogramming agent 
Salubrinal on TRAILR  Populations  
The TRAIL sensitivity of 4 cell lines was determined (fig 4) 
and subsequently, TRAILR populations isolated after 
persistent TRAIL-treatment by culture of surviving cells after 
TRAIL treatment. TRAILR populations were confirmed to be 
less sensitive to TRAIL than parental populations (fig 5). 
TRAIL did not synergistically enhance TRAIL responses in 
TRAILR cells (Fig 6). 
 
 
 
 
 
 
 
Figure 4. The percent apoptosis in lung cancer cell lines when exposed to 
TRAIL at 0150ng/ml for 24hours. Comparison of treated vs. untreated for each 
cell line is shown and assessed by Kruskal-Wallis multiple comparisons test 
(p<0.05=* P<0.01=** P<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Challenge of TRAILR cells with the translational 
reprogramming agent Salubrinal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6 Mean percent apoptosis in cell lines A549 (A) and A549 EML4-ALK (B) 
(ALK translocation) with combination treatments of Salubrinal (25µg/ml) and 
TRAIL (50ng/ml).  
Conclusions and future work. 
The cell lines A549, and NCI-H2170 do not contain a quiescent 
population. However more recent work has successfully isolated 
quiescent cells from other lung cancer cell lines (Fig 3). 
TRAIL-sensitive cell lines can readily be made TRAILR by persistent 
treatment with sub-toxic doses of TRAIL, mirroring clinical findings. 
TRAILR cells could not be sensitised to TRAIL by Salubrinal 
Ongoing work is aimed at assessing gene expression changes in 
TRAILR cells and assessing TRAIL resistance in quiescent cells in 
the new TWIT-Q cell line. 
Aims and Hypothesis 
The hypothesis of this study was that quiescent 
cells isolated from lung cancer could be 
translationally reprogrammed to bring them out 
of a resistant state. 
Aims: 
1) Isolate a quiescent phenotype within lung 
cancer cell lines. 
2) Induce translational reprogramming using 
drug Salubrinal and re-sensitize the population. 
Methods 
Non-proliferating cells from lung cancer cells 
were distinguished using lipophilic membrane 
PKH67 dye which is lost on cell proliferation 
and flow cytometry to identify PKH67Hi non-
proliferating cells. 
Apoptosis was assessed in response to TRAIL 
at 24 and 72 hours using Propidium Iodide and 
Hoechst 33342 staining.  
Cells were re-challenged with to establish a 
TRAIL resistant (TRAILR) population vs. the 
parent line 
•TRAILR cells were treated with Salubrinal 
(10/25µm) in combination with TRAIL cells to 
assess the effects of translational 
reprogramming on acquired TRAILR 
 
 
Results 
A549 does not contain a quiescent population, 
and all PKH67Hi cells were associated with 
spontaneous cell death (Fig 2) 
 
 
 
 
 
 
 
 
 
Figure 2. (A) A549 cells stained with Hoechst 33342 
and stimulated with 25ng/mL of TRAIL at 24 hours 
imaged using fluorescent microscopy to show apoptosis. 
(B) Images show PKH67Hi cells undergoing apoptosis 
when exposed to 25ng/mL of TRAIL at 72 hours in cell 
line A549 at 20x magnification.  
 
Identification of quiescent cells 
Flow cytometry was used to identify a population of cells 
which retained PKH67 over a 12 day period. In the A549 
cell lines, there was no high presence of PKH67 high 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Flow cytometry and fluorescent microscopy data of 
NCI-H2170 (TOP), NCI-H838 (MIDDLE), and TWIT-Q (BOTTOM) 
cells. Column (A) represents PKH67 stain populations compared 
to the parent strain taken at day 1 and column (B) represents the 
same cells taken at day 12.  Microscopy images taken using the 
FITC camera of the cells at the same time as flow cytometry are 
displayed underneath the corresponding flow cytometry data.  
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Figure 5. Mean percentage apoptosis 
in the parental lung cancer cell lines 
H2170 (A), A549 (B) and A549 EML4-
ALK (C) compared to the TRAILR 
isolated populations. Data is shown as 
Mean +/- SD and significance 
determined by Kruskal-Wallis test 
(p<0.05=* P<0.01=**). 
* 
* 
* 
0
20
40
60
80
100
0 25 50
P
e
rc
e
n
ta
ge
 D
e
ad
 c
e
lls
 (
%
) 
Trail concentration (ng/mL) 
Parent
strain
TRAIL
Treated
strain
B 
0
20
40
60
80
100
0 25 50
P
e
rc
e
n
ta
ge
 D
e
ad
 c
e
lls
 (
%
) 
Trail concentration (ng/mL) 
Parent
strain
TRAIL
treated
strain
C 
References Schewe, D& Aguirre-Ghiso (2009). Inhibition of 
eIF2  Dephosphorylation Maximizes Bortezomib Efficiency and 
Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome 
Inhibitor Therapy. Cancer Research, 69(4), 1545-1552. - 
Figure 1. Known TRAIL-sensitisers and mechanisms of 
action (Cross and Sayers, 2014) 
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